Experimental immunotherapy of colorectal carcinoma by monoclonal antibody ND4.
The potential for experimental immunotherapy of colorectal cancers by mouse IgG2a monoclonal antibody (MAb) ND4 is investigated. The MAb ND4 recognizes a 160 kd cell surface glycoprotein that is strongly expressed in 58% of colorectal carcinomas. The antibody is internalizable by MIP-101 colorectal carcinoma cells. Biodistribution studies in nude mice bearing MIP-101 subcutaneous tumors showed accumulation of 125I-ND4 MAb in tumors from 5% at 18 hours to 14% of the injected dose per gram tissue at 14 days after intraperitoneal (i.p.) injection. Experimental immunotherapy studies using 125I-ND4 in MIP-101 tumor-bearing nude mice showed 64% inhibition of tumor growth 2 weeks after two i.p. injections at 7-day intervals. The MAb ND4 may be useful as a therapeutic reagent for colorectal tumors.
Kelly
Timothy M
TM
Department of Surgery, Laboratory of Cancer Biology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02115, USA.
Thomas
Peter
P
Ganguly
Aniruddha
A
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000276:immunology; D045744:Cell Line, Tumor; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000276:immunology; D007155:Immunologic Factors / Q000627:therapeutic use*; D007167:Immunotherapy; D051379:Mice; D008807:Mice, Inbred BALB C; D008819:Mice, Nude
D000911:Antibodies, Monoclonal; D007155:Immunologic Factors